DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: Quetiapine fumarate (Drug); Duloxetine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Art Lazarus, MD, Study Director, Affiliation: AstraZeneca

Summary

This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.

Clinical Details

Official title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD

Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change from randomization to Week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score

Secondary outcome:

Change from randomization to each assessment in the MADRS total score

MADRS response, defined as a ≥50% reduction from randomization in the MADRS total score at Week 6

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient has a documented clinical diagnosis of Major Depressive Disorder.

- Be able to understand and comply with the requirements of the study.

- Able to understand and provide written informed consent

Exclusion Criteria:

- Patients (female) must not be pregnant or lactating

- Current or past diagnosis of stroke or transient ischemic attack (TIA).

Locations and Contacts

Research Site, Birmingham, Alabama, United States

Research Site, Scottsdale, Arizona, United States

Research Site, Beverly Hills, California, United States

Research Site, San Diego, California, United States

Research Site, Sherman Oaks, California, United States

Research Site, Wildomar, California, United States

Research Site, Bradenton, Florida, United States

Research Site, Orlando, Florida, United States

Research Site, Tampa, Florida, United States

Research Site, Boca Raton, Florida, United States

Research Site, Jacksonville, Florida, United States

Research Site, West Palm Beach, Florida, United States

Research Site, Edwardsville, Illinois, United States

Research Site, Lake Charles, Louisiana, United States

Research Site, Baltimore, Maryland, United States

Research Site, Haverhill, Massachusetts, United States

Research Site, Okemos, Michigan, United States

Research Site, St. Paul, Minnesota, United States

Research Site, St. Louis, Missouri, United States

Research Site, Princeton, New Jersey, United States

Research Site, Albuquerque, New Mexico, United States

Research Site, New York City, New York, United States

Research Site, Dayton, Ohio, United States

Research Site, Mayfield Village, Ohio, United States

Research Site, Oklahoma City, Oklahoma, United States

Research Site, Salem, Oregon, United States

Research Site, Philadelphia, Pennsylvania, United States

Research Site, Columbia, South Carolina, United States

Research Site, Memphis, Tennessee, United States

Research Site, Houston, Texas, United States

Research Site, Salt Lake City, Utah, United States

Research Site, Richmond, Virginia, United States

Research Site, Kirkland, Washington, United States

Research Site, Morgantown, West Virginia, United States

Additional Information

Starting date: April 2006
Last updated: July 31, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009